TEMPE, AZ / ACCESSWIRE / December 17, 2019 / Billy Baugham has over 25 years of experience in the aerospace and customer service industries. Thanks to his expertise, he has been able to help companies in areas such as maximizing operational impact, lean methodologies, and regulatory compliance. His work has led him to work with countries such as Pakistan, Egypt, Jordan, and Italy. Despite his experience in many sectors, Billy Baugham is most proud of the work he has done for the aerospace industry. He has worked with Honeywell Aerospace, U.S. Airways, and Safety Services Company. Billy Baugham shares the top trends in aerospace of 2019.

Cost Reduction Through Electric and Hybrid Engines

According to Billy Baugham, one of the biggest trends in aerospace is the need to cut back on emissions and overall costs. More and more aerospace experts want to focus on ways to preserve the environment through more eco-friendly options. They hope to achieve a more eco-friendly aircraft that consumes less fuel, releases fewer emissions, and exceeds performance expectations. To achieve these goals, aerospace experts are looking at hybrid engines and fuels.

Autonomous Flight Systems

Billy Baughman mentions that autonomous flight systems have been in the minds of those working in the aerospace industry for decades. Many aerospace engineers are working on developing enhanced technology specifically focused on helping autonomous drones and space vehicles to operate at even higher performance thresholds.

Expansion of MRO

Billy Baugham explains that aerospace technicians will place more emphasis on the MRO market. Because many airlines go over budget due to unplanned repairs and down-time, the aerospace industry will focus more on applying enhanced preventative maintenance. As new technology and data develops, operators will be able to better understand and predict how the systems of each aircraft operate most effectively. This, in turn, will significantly improve operating margins.

Consolidation of Aerospace Parts

A trend that is sure to revolutionize the aerospace industry, according to Billy Baugham, is the consolidation and streamlining of aircraft parts manufacturing. By consolidating parts into fewer pieces and using printing technology, engineers plan to make safer and lighter parts. This will cut down on assembly costs, manufacturing time and component weight. The production of consolidated parts will also make the supply chain more effective,

Aside from his extensive experience in aerospace, Billy Baugham has also led and presented discussions in front of Fortune 100 companies. He has also developed proposals for companies valued at more than $30 million, and enjoys volunteering and giving back to his community.

CONTACT:

Caroline Hunter
Web Presence, LLC
+1 7865519491

SOURCE: Web Presence, LLC

ReleaseID: 570593

ATLANTA, GA / ACCESSWIRE / December 18, 2019 / Findit, Inc. (OTC PINK:FDIT) owner of Findit.com, a social networking site which provides online marketing services, is featuring Findit member CBD Unlimited (EDXC) for its holiday shopping gift ideas with discounts up to 33%.

The Holiday Season is here and shoppers have less than a week to complete all of their holiday shopping for Christmas and Hanukkah. The company we are featuring today is CBD Unlimited who is a member on Findit that utilizes Findit's full service social networking content management online marketing services.

For those looking for great deals on premium quality CBD products, visit CBD Unlimited which is currently featuring their Holiday Deals where shoppers can save up to 33% on their purchase of specific CBD products.

CBD Holiday Deals!
CODE 33%OFFOILS
Get 33% off 10mL premium orange and peppermint oils

CBD Unlimited is a highly trusted developer of high end hemp derived cannabidiol products from CBD oils to concentrates, pet products, topicals and more.

CBD Unlimited is offering several different sales right now for the holidays

CODE: CBDU33%OFF30CAPS for 33% off 30 ct Premium Blue Capsules and Night Capsules

CODE: 25%OFFX at checkout to receive 25% off Premium Blue Balm X and Mist X

Findit offers a full suite of online social networking content creation programs to its members that are seeking to increase their overall online web presence, build brand awareness, increase the number of search results and improve their indexing positions in Google, Yahoo and Bing. Findit accomplishes this for CBD Unlimited along with other members on Findit by creating tailored content and sharing that content via social sites in addition to Findit that can include; Facebook, Twitter, Google My Business, LinkedIN and other sites that allow CBD related posts.

https://www.youtube.com/watch?v=bIIP4h8BOrQ&feature=emb_logo

Findit focuses on reaching the target demographics for each of these members that may or may not be aware of them in an effort to heighten brand awareness of their services and in some cases, their extensive product lines.

About Findit, Inc.

Findit, Inc., owns Findit.com which is a Social Media Content Management Platform that provides an interactive search engine for all content posted in Findit to appear in Findit search. The site is an open platform that provides access to Google, Yahoo, Bing and other search engines access to its content posted to Findit so it can be indexed in these search engines as well. Findit provides Members the ability to post, share and manage their content. Once they have posted in Findit, we ensure the content gets indexed in Findit Search results. Findit provides an option for anyone to submit URLs that they want indexed in Findit search result, along with posting status updates through Findit Right Now. Status Updates posted in Findit can be crawled by outside search engines which can result in additional organic indexing. All posts on Findit can be shared to other social and bookmarking sites by members and non-members. Findit provides Real Estate Agents the ability to create their own Findit Site where they can pull in their listing and others through their IDX account. Findit, Inc., is focused on the development of monetized Internet-based web products that can provide an increase in brand awareness of our members. Findit, Inc., trades under the stock symbol FDIT on the OTCPinksheets.

Safe Harbor:

This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including statements regarding potential sales, the success of the company's business, as well as statements that include the word believe or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Findit, Inc. to differ materially from those implied or expressed.

Contact:

Clark St. Amant
404-443-3224

SOURCE: Findit, Inc.

ReleaseID: 570647

Reports two hospitals now purchasing CompuFlo disposables with many more now trialing the system

LIVINGSTON, NJ / ACCESSWIRE / December 18, 2019 / Milestone Scientific Inc. (NYSE American:MLSS), a leading developer of computerized drug instruments that provide painless and precise injections, today provided a year-end update on the commercial roll-out of its CompuFlo® Epidural System.

Leonard Osser, Interim Chief Executive Officer of Milestone Scientific, stated, "We have made significant progress over the past year, setting the stage for the commercial rollout of the CompuFlo® Epidural System in 2020, which we believe will be a turning point for the Company. Our primary focus in 2019 was successfully trialing our CompuFlo Epidural System in multiple hospitals and medical schools-placing the system with key opinion leaders, continuing important clinical studies and working with anesthesiologists in the U.S. and Europe. This was a necessary first step to establish credibility before these institutions would formally adopt and begin broader deployment of the CompuFlo® Epidural System. I am pleased to report the feedback thus far has been positive and the CompuFlo® Epidural System has exceeded our expectations with over two thousand successful procedures to date. This is a significant achievement compared to the traditional loss of resistance technique, which has a high associated medical risk and morbidity. Given our success, and consistent with our rollout strategy, we are in the final stages of several important commercial agreements and look forward to providing further updates in the weeks ahead."

Brent Johnston, President of Milestone Scientific, commented, "Going forward, our commercial rollout strategy involves several key steps. Firstly, we are building upon the nine completed and published clinical studies and have begun meeting with Group Purchasing Organizations (GPO) in order to obtain approval of the CompuFlo® Epidural System within their facilities. Some of these GPOs have between 3,000 to 5,000 hospitals within their network. Getting this approval should shorten the sales cycle and open us up to large markets. Part of that GPO strategy was getting on the federal schedule, which we achieved through our contract with RedOne, which now allows us to sell into all federal medical facilities."

"Secondly, we are meeting with insurance carriers to garner their support on making the CompuFlo® Epidural System the preferred technique for performing epidural injections. This is based on the strong clinical data showing a 100% reduction in epidural punctures and complication rates by using the CompuFlo® Epidural System, as seen in the Hidalgo study published in the Open Journal of Anesthesiology, October 2019, in which 600 cases were completed without a single dural puncture. This and several other studies have proven the validity of the CompuFlo® Epidural System, which not only benefits patients but also should lower the cost associated with treating these complications. Up until now, there have been no other available procedures in the labor and delivery setting since 1921. We can now demonstrate a significant economic value proposition to both of these entities."

Mr. Osser continued, "Given the positive feedback thus far, we are very encouraged for the future of our Company. While we believe that our system can be used for a variety of epidural procedures and other medical applications, our initial focus is on the labor and delivery market. With close to four million births in the U.S. each year, we believe the risk factors and potential liability associated with the traditional loss of resistance technique, make this market ideally suited to new technologies. In terms of the broader epidural market, over $5 billion is spent annually on epidural injections in the US alone, with over 11 million epidural procedures performed each year in the US and over 30 million worldwide. At present, we have two hospitals purchasing our disposables with many more trialing our system."

"It is also worth noting that the recent increase in the authorized share count was intended to reverse a liability and associated non-cash charge of $1.9 million recorded in the third quarter of 2019, related to an insufficient number of authorized shares of common stock that may be issued upon the exercise of outstanding warrants. As a result of the increase in authorized shares, we expect these charges to be reversed in the fourth quarter of 2019. I would like to personally thank all of our shareholders for your continued support and we look forward to an exciting year in 2020."

About Milestone Scientific Inc.

Milestone Scientific Inc. (MLSS) is a biomedical technology research and development company that patents, designs, develops and commercializes innovative diagnostic and therapeutic injection technologies and instruments for medical, dental, cosmetic and veterinary applications. Milestone's computer-controlled systems are designed to make injections precise, efficient, and virtually painless. Milestone's proprietary DPS Dynamic Pressure Sensing technology® is our technology platform that advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for cosmetic botulinum toxin injections, epidural space identification in regional anesthesia procedures and intra-articular joint injections. For more information please visit our website: www.milestonescientific.com.

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2018. The forward-looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Contact:

David Waldman or Natalya Rudman
Crescendo Communications, LLC
Email: mlss@crescendo-ir.com
Tel: 212-671-1020

SOURCE: Milestone Scientific Inc.

ReleaseID: 570563

TORONTO, ON / ACCESSWIRE / December 18, 2019 / Matica Enterprises Inc. (CSE:MMJ)(Frankfurt:39N)(OTCQB:MMJFF) ("Matica" or the "Company") is pleased to welcome Mr. Roop Mundi to the board of directors of the Company, subject to regulatory approval. As a former securities lawyer and retailer of CBD products in his own right, Mr. Mundi brings a unique skill set to the board of Matica.

Mr. Roop Mundi currently serves as Chief Executive Officer of Infuzed Brands Inc. Infuzed is a beverage company that focuses on CBD infused beverages. Infuzed is available in over 150 retail locations across the United States. In addition, Mr. Mundi owns and operates Mundi Capital Ventures – a private equity firm focused on consumer products distribution and logistics. Included in Mundi Capital's investment portfolio is Jilong Plastic Products (North America) Inc. which is the sales, marketing and logistics arm of Shanghai Jilong Plastic Products – the third largest PVC producer of consumer goods worldwide. Mundi Capital currently provides logistics services and solutions for Weveel Products LLC, LoopScooters, Volm Industries and GrillTime Inc. Since its inception in 2015, Mundi Capital has successfully exited in three portfolio companies with an average multiple of 4 times total investment amount.

Prior to Mundi Capital, Mr. Mundi served as Vice President, General Counsel of RCI Capital Group Inc., a private equity firm based in Vancouver focused on Asia based transactions in the technology and energy markets. In addition, Mr. Mundi was Vice President, General Counsel of Kingsdale Shareholder Services Inc., the largest proxy and corporate governance firm in Canada. Prior to Kingsdale, Mr. Mundi was an Associate at Cassels Brock & Blackwell LLP focusing on corporate finance and securities in the real estate, technology and mining sectors. Mr. Mundi currently sits on the Board of Directors for Loopshare Ltd. Loopshare is publicly listed and is an emerging global leader in ridesharing, micro-mobility and sustainable transportation. Mr. Mundi holds a Bachelor's degree from North Carolina State University, a Master's degree from the University of Toronto and a law degree from the University of British Columbia.

About Matica

Matica is a multi-faceted, innovative company in the Quebec cannabis space. RoyalMax Biotechnology Canada Inc. has been granted a standard cultivation licence by Health Canada and is currently awaiting processing and sales licences. In the township of Hemmingford, Matica is building 1,000,000 square feet of greenhouse growing space, in 200,000 square foot increments, on a sprawling 181 acre property.

For more information on Matica Enterprises please visit the website at: www.maticaenterprises.com.

On behalf of the Board of Directors

MATICA ENTERPRISES INC.

Boris Ziger
Boris Ziger, CEO & Chairman
The Company's public filings are available for review at www.sedar.com and www.thecse.com.

For further information, please contact Boris Ziger, at:

Telephone: 416-304-9935
E-mail: info@maticaenterprises.com
Website: www.maticaenterprises.com , www.maticammj.com

Disclaimer for Forward-Looking Information

Certain information in this press release may constitute forward-looking information. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Corporation assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward looking-statements unless and until required by securities laws applicable to the Corporation. Additional information identifying risks and uncertainties is contained in the Corporation's filings with the Canadian securities regulators, which filings are available at www.sedar.com.

This news release contains statements about the Company's information that may be made available on the S&P Capital IQ Corporation Records Listing Program and the business of Matica that are forward-looking in nature and as a result, are subject to certain risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, undue reliance should not be placed on them as actual results may differ materially from the forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof, and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, except as required by law.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. We seek Safe Harbor.

SOURCE: Matica Enterprises Inc

ReleaseID: 570632

Three-arm, three-month study will compare Viveve's cryogen-cooled monopolar radiofrequency (CMRF) treatment and cryogen-only sham to an inert sham treatment

ENGLEWOOD, CO / ACCESSWIRE / December 18, 2019 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, announced today that it has received approval of its Investigational Testing Application (ITA) from the Canadian Ministry of Health to conduct a three-arm, three-month feasibility study to compare Viveve's cryogen-cooled monopolar radiofrequency (CMRF) treatment and a cryogen-only sham to an inert sham treatment for the improvement of stress urinary incontinence (SUI) in women.

"Our prior clinical research indicates that our advanced CMRF technology could play an important role in the treatment of SUI for millions of women around the world. We are pleased to have received approval from Health Canada to initiate a short-term SUI feasibility study and our outstanding team of investigators and trial sites are positioned to move forward rapidly," said Scott Durbin, Viveve's chief executive officer and director. "This trial represents a significant advance in our strategy to pursue label expansions for Viveve's CMRF technology to maximize the commercial potential of our platform."

In August 2019, Viveve presented results from the LIBERATE-International SUI clinical trial comparing use of the Viveve Treatment (cryogen cooling and 90 Joules/cm2 RF energy) to use of cryogen-only treatment (cryogen cooling with only 1 Joule/cm2 RF energy, identified in the study as "sham treatment") for improvement of SUI in women. Results from this trial showed that both treatments had a clinically meaningful effect on objective and subjective outcomes in patients, although the treatment effects were not statistically different from each other.

"The results from our LIBERATE-International trial provided us with many essential insights indicating the potential efficacy benefits of Viveve's CMRF technology in the treatment of mild to moderate SUI in women and enabled us to determine the optimal path forward for this development program. We look forward to working with our team of investigators to complete this trial in the coming months," Mr. Durbin added.

Pending Investigational Review Board approvals of the ITA cleared SUI treatment protocol, the Company anticipates rapid study initiation and subject enrollment with a potential data readout in the second quarter of 2020. If the results are positive, showing a definitive difference between the study arms, the Company intends to resubmit its pending Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for approval to conduct the LIBERATE-U.S. trial for improvement of mild to moderate SUI in women. SUI is a condition that affects an estimated 25-30 million women worldwide.

About the International SUI Feasibility Study

The international three-arm SUI feasibility study is a prospective, randomized, single-blind clinical trial comparing use of the Viveve cryogen-cooled monopolar radiofrequency (CMRF) treatment and a cryogen-only sham to an inert sham treatment in women with SUI. Three clinical trial sites in Canada will enroll a total of approximately 36 subjects (12 per treatment arm) randomized on a 1:1:1 ratio to each of the three study arms. The primary efficacy endpoint is the mean change from baseline in the standardized 1-hour Pad Weight Test at three months post-treatment. The treatment protocol will assess additional objective endpoints including the 24-hour Pad Weight Test and 3-day voiding diary at three months post-treatment. The study design also includes exploratory endpoints as well as safety follow-up throughout the study.

About Viveve

Viveve Medical, Inc. is a medical technology company focused on women's intimate health. Viveve is committed to advancing new solutions to improve women's overall well-being and quality of life. The internationally patented Viveve® System incorporates CMRF technology to uniformly deliver volumetric heating while gently cooling surface tissue to generate neocollagenesis in a single in-office session.

In the United States the Viveve System is cleared by the FDA for use in general surgical procedures for electrocoagulation and hemostasis. International regulatory approvals and clearances have been received for vaginal laxity and/or improvement in sexual function indications in more than 50 countries. Viveve is conducting VIVEVE II, a multicenter, randomized, double-blind, sham-controlled clinical trial to assess improvement of sexual function in women following vaginal childbirth. Completion of full 250 subject enrollment was announced in early March 2019. The top-line 12-month data readout of the VIVEVE II trial is expected in April 2020. If successful, VIVEVE II results could support a marketing application for a new U.S. commercial indication.

For more information visit Viveve's website at www.viveve.com.

Safe Harbor Statement

All statements in this press release that are not based on historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. While management has based any forward-looking statements included in this press release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of our control, which could cause actual results to materially differ from such statements. Such risks, uncertainties and other factors include, but are not limited to, the fluctuation of global economic conditions, the performance of management and our employees, our ability to obtain financing or pursue strategic alternatives, our ability to obtain approval or clearance for sale of our medical device for all indications sought, competition, general economic conditions and other factors that are detailed in our periodic and current reports available for review at www.sec.gov. Furthermore, we operate in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware, unless required by law.

Investor Relations contacts:

Amato and Partners, LLC
Investor Relations Counsel
admin@amatoandpartners.com

Media contact:

Jenna Urban
Berry & Company Public Relations
(212) 253-8881
jurban@berrypr.com

SOURCE: Viveve Medical, Inc.

ReleaseID: 570628

NIJMEGEN, THE NETHERLANDS / ACCESSWIRE / December 18, 2019 / The Dutch company Xenikos B.V., which develops innovative immunotherapies for treating patients with severe immune disease and post-transplant rejection, announced today that the first patient has been treated in their U.S.-based Phase 3 registration trial designed to evaluate the use of T-Guard for treating steroid-refractory acute graft-versus-host disease (SR-aGVHD) in patients following allogeneic stem cell transplantation.

This pivotal Phase 3 trial (BMT CTN 1802; clinicaltrials.gov NCT04128319) is designed to evaluate the efficacy and safety of T-Guard in patients who receive an allogeneic stem cell transplant and subsequently develop SR-aGVHD. A total of 47 patients will be enrolled through up to 25 transplant centers in the U.S. The trial is supported by the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) and is co-funded by the National Heart, Lung, and Blood Institute (NHLBI) and the National Cancer Institute (NCI), both part of the National Institutes of Health.

In this single-arm, multi-center study, patients who have been diagnosed with SR-aGVHD will receive four infusions of T-Guard over the course of a week. The primary endpoint of the study is the complete response rate on day 28, and secondary endpoints include duration of complete response, overall response rate, and overall survival rate six months after treatment.

"We are delighted to start this registration trial, which represents a major step forward in helping bring T-Guard to patients," said Dr. Ypke van Oosterhout, Chief Executive Officer of Xenikos. "With the BMT CTN's vast network of leading transplant centers throughout the U.S., and their experience conducting clinical trials, we believe they will be able to recruit sufficient numbers of patients quickly. Effective new therapies for treating SR-aGVHD are urgently needed, and we believe that T-Guard may provide patients with an effective new option for treating this devastating and potentially fatal condition."

"Acute GVHD is a life-threatening complication of hematopoietic stem cell transplantation, and better treatments are urgently needed, particularly for patients with steroid-refractory acute GVHD, for which only limited therapeutic options are currently available, resulting in an extremely poor long-term prognosis," said Dr. Mehdi Hamadani of the BMT CTN. "The preliminary data obtained with T-Guard are promising, and we look forward to helping bring this new therapy through the final phase of development and into the clinic."

T-Guard: helping reset the body's immune system

T-Guard is designed to safely and swiftly reset the body's immune system in life-threatening T cell‒mediated conditions, including transplant-related rejection, acute solid-organ rejection, and severe autoimmune disease. T-Guard consists of a unique combination of toxin-conjugated monoclonal antibodies that target CD3 and CD7 molecules on T cells and NK cells. Preclinical and early clinical testing have shown that T-Guard can specifically identify and eliminate mature T cells and NK cells with minimal treatment-related side effects. Importantly, T-Guard's action is short-lived, thereby significantly reducing the patient's vulnerability to opportunistic infections compared to currently available therapies. Xenikos successfully completed a Phase 1/2 study for the second-line treatment of SR-aGVHD in patients following hematopoietic stem cell transplantation (HSCT), showing that just one week of T-Guard treatment induced a remarkably high complete response rate and a doubling of the 6-month overall survival rate as compared to institutional historical controls. These results were published in the peer-reviewed journal Biology of Blood and Marrow Transplantation. T-Guard has been granted Orphan Drug Designation status in both the EU and the U.S., and a Phase 3 registration trial evaluating T-Guard for the treatment of SR-aGVHD is currently underway in the U.S (NCT04128319).

About acute graft-versus-host disease

Following allogeneic stem cell transplantation, most patients have a high risk of developing graft-versus-host disease (GVHD), and this risk increases considerably in older patients. With GVHD, the donor's immune cells attack the patient's cells. Acute GVHD occurs early after transplantation and can be relatively mild or quite severe, even life-threatening, if not treated. Although GVHD can often be treated successfully with steroids, few options are available if the disease progresses or becomes resistant to steroid treatment, and the long-term survival of patients with steroid-refractory acute GVHD is less than 20%, highlighting the urgent need for effective therapies.

About Xenikos B.V.

Xenikos develops innovative immunotherapies based on conjugated antibodies. This novel therapeutic approach helps reset the immune system in patients who have a severe immune disease or have developed post-transplantation rejection. A Phase 3 registration trial evaluating the Company's flagship product, T-Guard(R) for the treatment of steroid-refractory acute graft-versus-host disease is currently underway in the U.S. (NCT04128319).

For more information, visit us at www.xenikos.com.
Follow us on LinkedIn.

About the BMT CTN

The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) conducts rigorous multi-institutional clinical trials of high scientific merit, with a focus on improving the survival and outcome of patients who undergo hematopoietic cell transplantation or receive cellular therapy. The BMT CTN has completed 40 Phase 2 and Phase 3 trials at more than 100 transplant centers, with over 11,000 study participants.

The BMT CTN is funded by the National Heart, Lung, and Blood Institute and the National Cancer Institute at the U.S. National Institutes of Health (NIH) and represents the collaborative efforts of 20 core transplant centers/consortia, the Center for International Blood and Marrow Transplant Research (CIBMTR), the National Marrow Donor Program (NMDP)/Be The Match, and the Emmes Company, LLC, a contract research organization. CIBMTR is a research collaboration between the NMDP/Be The Match and the Medical College of Wisconsin.

More information about the BMT CTN can be found at www.bmtctn.net.

For further information, please contact:

Corporate contact:
Media contact:

Xenikos B.V.
Ypke van Oosterhout, PhD
Chief Executive Officer
Phone: +31 24 3000100
Mobile: +31 6 11017611
Email: y.vanoosterhout@xenikos.com
MC Services AG
Dr. Solveigh Mähler

Phone: +49 211 529 252 19
Mobile: +49 171 656 382 74
Email: solveigh.maehler@mc-services.eu

 
For U.S. inquiries:
Laurie Doyle
Phone: +1 339 832 0752
Email: laurie.doyle@mc-services.eu

SOURCE: Xenikos B.V.

ReleaseID: 570646

Trace Analytics Inc. is a leading scalable analytics cannabis/cannabinoid laboratory poised to meet the demands for mandated regulatory cannabis/cannabinoid testing

WSDA contracted Trace Analytics for the purpose of doing cannabinoid profiling for the State's industrial hemp program to ensure the percentages of certain cannabinoids are below Federal limits

BEVERLY HILLS, CA / ACCESSWIRE / December 18, 2019 / Applied BioSciences Corp. (OTCQB:APPB) ("Applied" or the "Company"), today announced that the Washington State Department of Agriculture (WSDA) has extended its contract for services with Applied's majority owned subsidiary, Trace Analytics Inc. ("Trace").

The WSDA contracted Trace beginning in July 2019 for the testing of Industrial Hemp samples and percentage testing for delta 9-tetrahydrocannabidiol (THC) and delta 9-tetrahydocannabinolic acid (THC-A) to ensure the percentages of certain cannabinoids are below Federal limits.

"We are grateful for our relationship with the WSDA and are pleased to continue cannabinoid profiling for the WSDA's Industrial Hemp program. The testing and reporting of results that we have conducted to date have demonstrated the quality of our analytics and our dedication to ensuring compliance with Federal limits," stated Jason Zitzer, Chief Operating Officer of Trace Analytics. "We provide expert consulting services to government entities at all levels around the world and are appreciative to WSDA to have been selected as the sole lab to conduct their testing. This contract extension provides another opportunity toward establishing a higher quality for cannabis and hemp testing."

Trace Analytics Inc. is a leading cannabis science and technology company with significant footprints in lab testing, research and development and licensing. Trace Analytics was started by a group of scientists who specialized in analytical chemistry, genetics and molecular biology, focused on ensuring compliance with public safety standards and end user safety. Trace Analytics is in the process of expanding throughout the United States, and globally with the goal of helping the rest of the world adopt "best practices" in cannabis and hemp testing. The Company also provides expert consulting services to legislators and regulators in many countries, states and municipalities around the world.

Based on Applied BioSciences' stated strategic corporate shift to focus on its BioPharma division and the development and commercialization of novel therapeutics that target the endocannabinoid system (ECS), the Company is currently evaluating a strategic transaction of Trace Analytics. Applied is currently in late-stage discussions and expects to close the transaction by year end.

About Applied BioSciences Corp.

Applied BioSciences is a vertically integrated company focused on the development and commercialization of novel, science-driven, synthetic cannabinoid therapeutics / biopharmaceuticals that target the endocannabinoid system to treat a wide-range of diseases across multiple therapeutic areas. We also deliver high-quality consumer and OTC THC-free CBD products that promote overall health and wellbeing as well as state-of-the-art testing and analytics capabilities to our customers. For more information, visit appliedbiocorp.com and connect with the Company on Twitter, Facebook and LinkedIn.

Safe Harbor Statement

Except for historical information contained herein, statements in this release may be forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Applied Biosciences Corp. (the "Company") or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in the Company's filings with the Securities and Exchange Commission. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as (i) the development and protection of our brands and other intellectual property, (ii) the need to raise capital to meet business requirements, (iii) significant fluctuations in marketing expenses, (iv) the ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of our products and services, (v) the Company's ability to conduct the business if there are changes in laws, regulations, or government policies related to cannabis, (vi) management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and (vii) other information that may be detailed from time to time in the Company's filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor and Media Contact:

IR@appliedbiocorp.com
(833) 475-8247

SOURCE: Applied BioSciences Corp.

ReleaseID: 570538

ReleaseID: 570604

Flexpoint's Occupancy and Impact Sensors to play a significant role in the world of autonomous cars in addition to conventional vehicles

DRAPER, UT / ACCESSWIRE / December 18, 2019 / As top automakers are investing billions in artificial intelligence for self-driving vehicles, Flexpoint Sensor Systems Vehicle Impact Sensors as well as Occupancy Sensor are positioned to play a significant role in the world of autonomous cars in the coming months and years. The first self-driving cars which will be monitored by an automated system as opposed to a human driver with automated assistance, could be released as soon as 2024. Flexpoint Sensor Systems is equipped with the technology needed to further the research, development and final product ready for consumer purchase.

"Flexpoint has entered into a non-disclosure agreement with a major automotive maker to discover how our Occupancy Sensor and Impact Sensor, can better improve the safety qualities of a self-driving vehicle," said Clark Mower, CEO of Flexpoint Sensor Systems. "As early innovators of seat and impact sensor technology, we have much to offer as the self-driving systems are developed for the production car."

Mower added, "Flexpoint is also currently involved in similar and additional applications for major automobile manufacturers of conventional vehicles for both US and international markets. "

The Flexpoint Occupancy Sensor, which has the ability to detect the difference between a human, an infant car seat, or even a bag of groceries or other heavy items, was developed nearly fifteen years ago with the intention of use alongside the required airbags in cars today. But with the higher safety demands of an artificially intelligent car now in play, Flexpoint's sensor has become the answer to the question: who and what is in the driverless car? And how do we protect people and property surrounding the car itself?

Emerging applications for Occupancy and Impact Sensors as well as new opportunities for BXS Battery Expansion Sensors and Interactive Gloves create an exciting future for the coming year.

The newest product, Flexpoint's Battery Expansion Sensor, continues to make progress as the partnerships with major companies who rely on lithium ion batteries in smaller spaces will utilize the expansion sensor as a safety measure.

"Internal testing is coming to an end and White Papers will be available in January, 2020," said Dave Beck, Vice President of Engineering for Flexpoint. "We continue to work with major manufacturers on improving the quality and quantity of data we are able to utilize to keep lithium batteries safe in consumer products."

Flexpoint has also received new purchase orders from multiple long standing partners for repeat orders for Flexpoint's sensors to be used in Interactive Gloves. Pioneered by Flexpoint fifteen years ago, the applications and improvements on the gloves for music, gaming and even surgery have become numerous. Additional orders are anticipated in early 2020 from these and other companies.

The leading supplier of thin film sensing technology, Flexpoint is dedicated to delivering the most innovative and cost-effective solutions to companies around the globe.

About Flexpoint Sensor Systems, Inc.

Flexpoint Sensor Systems, Inc. (OTC PINK:FLXT) is an innovative technology firm specializing in developing products that feature the Company's patented Bend Sensor® and related technology. The Bend Sensor® is a groundbreaking sensing solution that is revolutionizing applications in the automotive, safety, medical and industrial industries. The Bend Sensor® single-layer, thin film construction cuts costs and mechanical bulk while introducing a range of functions and stylistic design possibilities that have never before been available in sensing technology. Flexpoint's technology and expertise have been recognized by the world's elite business and academic innovators for over 17 years. The company is setting a new standard for sensing solutions in the "smart" age of technology.

Forward-Looking Statements

This press release contains certain forward-looking statements. Investors are cautioned that certain statements in this release are "forward-looking statements" and involve both known and unknown risks, uncertainties and other factors. Such uncertainties include, among others, certain risks associated with the operation of the company described above. The Company's actual results could differ materially from expected results.

Contact Information:

Flexpoint Sensor Systems
Clark Mower, President
801-568-5111

Brokers and Analysts
Chesapeake Group
410-825-3930

SOURCE: Flexpoint Sensor Systems, Inc.

ReleaseID: 570615

VANCOUVER, BC / ACCESSWIRE / December 18, 2019 / Prophecy Development Corp. ("Prophecy" or the "Company") (TSX:PCY)(OTCQX:PRPCF)(Frankfurt:1P2N) is pleased to announce that phase two drilling has started at its Pulacayo-Paca silver-zinc-lead project in Bolivia. It is a 5,000-meter program that will consist mainly of wide step-out drilling up to 1.5km west (Western Block) of the current 43-101 Pulacayo resource. That current Pulacayo resource covers 1.4 km in strike and represents only a small portion of the Tajo vein system which is over 3 km in strike and open to least 1,000 meters at depth, according to historical records of underground mining.

Joaquin Merino, Prophecy's VP for South American Operation, states: "Current artisanal mining at the surface serves as strong evidence that the Tajo vein (where underground mining took place from early 1800 to 1952) projects to surface at the Western Block. Pulacayo is a very large system and with this program we will test the boundaries of mineralization near the surface and its continuity along strike." The drill program is fully funded with a recent $3.9 million equity financing backed by Mr. Eric Sprott.

The Pulacayo deposit currently has a NI43-101 compliant resource of 2.08 million tonnes at Ag 455 g/t, Pb 2.18%, Zn 3.19% in the indicated category. It also has 0.48 million tonnes at Ag 406 g/t, Pb 2.08%, Zn 3.93% in the inferred category. The Company estimates that the amounts of metals of the indicated category are 30.4 million ounces of silver, 100.0 million pounds of lead, and 146.3 million pounds of zinc. The Company estimates that the amounts of metals of the inferred category are 6.3 million ounces of silver, 22.0 million pounds of lead, and 41.6 million pounds of zinc (see Company report "UPDATED MINERAL RESOURCE ESTIMATE TECHNICAL REPORT for the PULACAYO PROJECT," by Mercator effective October 20, 2017; available at SEDAR.COM).

The Company recently (October 2019) successfully completed phase one drilling: a 1,000 meter program at its satellite Paca project (see the Company's October 28, 2019 press release).

Phase two drill plan maps are available at www.prophecydev.com/company-presentation.

The Company expects to receive the first set of assay results in February, 2020.

Qualified Person

The technical contents of this news release have been prepared under the supervision of Danniel Oosterman, VP Exploration. Mr. Oosterman is not independent of the Company in that he is employed by it. Mr. Oosterman is a Qualified Person ("QP") as defined in the NI 43-101 guidelines.

About Prophecy

Prophecy is developing Pulacayo silver project in Bolivia and Gibellini vanadium project in Nevada. Further information on Prophecy can be found at www.prophecydev.com.

PROPHECY DEVELOPMENT CORP.
ON BEHALF OF THE BOARD

"Michael Doolin"
Chief Executive Officer

For more information about Prophecy, please contact Investor Relations

+1.604.569.3661 ext. 101
ir@prophecydev.com www.prophecydev.com

Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements

Certain statements contained in this news release, including statements which may contain words such as "expects", "anticipates", "intends", "plans", "believes", "estimates", or similar expressions, and statements related to matters which are not historical facts, are forward-looking information within the meaning of applicable securities laws. Such forward-looking statements, which reflect management's expectations regarding Prophecy's future growth, results of operations, performance, business prospects and opportunities, are based on certain factors and assumptions and involve known and unknown risks and uncertainties which may cause the actual results, performance, or achievements to be materially different from future results, performance, or achievements expressed or implied by such forward-looking statements.

These factors should be considered carefully, and readers should not place undue reliance on the Prophecy's forward-looking statements. Prophecy believes that the expectations reflected in the forward-looking statements contained in this news release and the documents incorporated by reference herein are reasonable, but no assurance can be given that these expectations will prove to be correct. In addition, although Prophecy has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. Prophecy undertakes no obligation to release publicly any future revisions to forward-looking statements to reflect events or circumstances after the date of this news or to reflect the occurrence of unanticipated events, except as expressly required by law.

SOURCE: Prophecy Development Corp.

ReleaseID: 570570